Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820956 | 1.00 | ATM (0.43) | ATMMAPTCTSKCTSSAAK1 | |
| SCHEMBL6678343 | 0.87 | ESR1 (0.40) | ATMMAPTCTSKCTSSAAK1 | |
| SCHEMBL7676598 | 0.84 | CTSS (0.41) | ATMCTSKCTSSAAK1CTSL | |
| SCHEMBL4598030 | 0.83 | ATM (0.44) | ATMMAPTCTSKCTSSKMT2A | |
| SCHEMBL30890670 | 0.83 | ATM (0.44) | ATMMAPTCTSKCTSSKMT2A | |
| SCHEMBL4381767 | 0.83 | ATM (0.44) | ATMMAPTCTSKCTSSKMT2A | |
| SCHEMBL21442814 | 0.82 | AAK1 (0.44) | MAPTCTSKCTSSAAK1CTSL | |
| SCHEMBL20181312 | 0.82 | AAK1 (0.44) | MAPTCTSKCTSSAAK1CTSL | |
| SCHEMBL25472039 | 0.82 | HTT (0.56) | ATMMAPTCTSKCTSSAAK1 | |
| SCHEMBL1343848 | 0.82 | HTT (0.56) | ATMMAPTCTSKCTSSAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786998-B1 | THIENYL [3, 2-D]PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2018-07-25 | — | — | EP | disclosed |
| US-9045491-B2 | Thienyl [3,2-D] pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-06-02 | — | — | US | disclosed |
| US-8906914-B2 | Ethylene diamine modulators of fatty acid hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-09 | — | — | US | disclosed |
| US-20140323466-A1 | THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-30 | — | — | US | disclosed |
| EP-2786998-A1 | THIENYL [3, 2-D]PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-10-08 | — | — | EP | disclosed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | disclosed |
| US-7470815-B1 | Selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006098554-A1 | NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-21 | — | — | WO | disclosed |
| US-20050159363-A1 | Selective neuronal nitric oxide synthase inhibitors | SILVERMAN RICHARD B (US) | 2005-07-21 | — | — | US | disclosed |
| US-6803486-B2 | PEPTIDOMIMETIC; N-AMINOBUTYL-N'-NITROGUANIDINE DERIVATIVES | NORTHWESTERN UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-20030119751-A1 | Selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY | 2003-06-26 | — | — | US | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| WO-2003000198-A2 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159363-A1 | Selective neuronal nitric oxide synthase inhibitors | NOS1, NOS3, NOS2 | ATM 4359/4885MAPT 823/4885CTSK 2298/4885 |
| US-20140323466-A1 | THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | DPP4, DPP7, DPP3 | ATM 4477/4885MAPT 4003/4885CTSK 1867/4885 |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | FAAH, FAAH2, APEH | ATM 3381/4885MAPT 2208/4885CTSK 1327/4885 |
| US-20030119751-A1 | Selective neuronal nitric oxide synthase inhibitors | NOS1, NOS3, NOS2 | ATM 4359/4885MAPT 823/4885CTSK 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.